American journal of preventive cardiology · 2025
Association between baseline white blood cell count and future cardiovascular events in patients with stable coronary artery disease- Sub-analysis of the REAL-CAD trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okada Kozo, Hibi Kiyoshi, Misumi Toshihiro, Iwahashi Noriaki, Gohbara Masaomi, Uemura Kohei, Iwata Hiroshi, Fukumoto Yoshihiro, Hiro Takafumi, Ozaki Yukio, Iimuro Satoshi, Sakuma Ichiro, Hokimoto Seiji, Miyauchi Katsumi, Matsuyama Yutaka, Nakagawa Yoshihisa, Ogawa Hisao, Daida Hiroyuki, Shimokawa Hiroaki, Saito Yasushi, Kimura Takeshi, Matsuzaki Masunori, Kimura Kazuo, Nagai Ryozo
Аннотация
BACKGROUND: Elevated white blood cell (WBC) counts have been associated with major adverse cardiovascular events (MACE). However, their incremental prognostic values, especially considering factors such as race, sex difference, clinical characteristics, and statin dosage, are not well defined. This study aimed to explore the relationship between baseline WBC counts and subsequent MACE in Japanese patients with stable coronary artery disease (CAD) receiving high and low doses of pitavastatin, as a sub-analysis of the REAL-CAD study.
METHODS AND RESULTS: A total of 10,123 patients with baseline WBC count data were included in this analysis. Patients were categorized into quartiles based on their baseline WBC counts, and the cumulative 4-year incidence of MACE, defined as cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring hospitalization, was compared among the quartiles. MACE occurred in 491 patients, and Kaplan-Meier curve analysis showed a significantly higher incidence of MACE in the fourth quartile compared with the first quartile (hazard ratio [HR]: 1.910, 95 % confidence interval [CI]: 1.477-2.471). Multivariate analysis indicated that the highest quartile of WBC count was an independent determinant of future MACE (HR: 1.879, 95 %CI: 1.439-2.454), adjusting for age, sex, diabetes, current smoking, statin dosage, and baseline high-sensitive C-reactive protein.
CONCLUSIONS: Elevated WBC counts increased the risk of cardiovascular events in Japanese patients with stable CAD, highlighting the importance of inflammation as a residual risk after statin treatments in the Japanese population. Further research is needed to evaluate the clinical benefits of screening and treatment strategies based on WBC counts.
METHODS AND RESULTS: A total of 10,123 patients with baseline WBC count data were included in this analysis. Patients were categorized into quartiles based on their baseline WBC counts, and the cumulative 4-year incidence of MACE, defined as cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring hospitalization, was compared among the quartiles. MACE occurred in 491 patients, and Kaplan-Meier curve analysis showed a significantly higher incidence of MACE in the fourth quartile compared with the first quartile (hazard ratio [HR]: 1.910, 95 % confidence interval [CI]: 1.477-2.471). Multivariate analysis indicated that the highest quartile of WBC count was an independent determinant of future MACE (HR: 1.879, 95 %CI: 1.439-2.454), adjusting for age, sex, diabetes, current smoking, statin dosage, and baseline high-sensitive C-reactive protein.
CONCLUSIONS: Elevated WBC counts increased the risk of cardiovascular events in Japanese patients with stable CAD, highlighting the importance of inflammation as a residual risk after statin treatments in the Japanese population. Further research is needed to evaluate the clinical benefits of screening and treatment strategies based on WBC counts.